PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Imidapril→

Imidapril PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
89371-37-9
Molecular formula
C20H27N3O6
Molecular weight
405.4 g/mol
Drug class
Angiotensin-converting enzyme (ACE) inhibitorantihypertensive prodrug
Mechanism of action
Imidapril is hydrolysed to the active metabolite imidaprilat, which competitively inhibits angiotensin-converting enzyme. This reduces angiotensin II formation and aldosterone secretion, lowers peripheral vascular resistance and blood pressure, and reduces sodium and water retention.
Indications / reported uses
  • Treatment of essential hypertension.
  • Use in selected patients with chronic heart failure or diabetic nephropathy has been described in clinical studies and depends on local product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5464343 · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6377&tab=clinical · https://pubmed.ncbi.nlm.nih.gov/17547476/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Imidapril PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Imidapril Permitted Daily Exposure (PDE) report (the Imidapril PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Imidapril Occupational Exposure Limit (OEL) report (the Imidapril OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.